The latest trading session saw Boston Scientific (BSX) ending at $84, denoting a +0.1% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.15%, while the tech-heavy Nasdaq appreciated by 0.15%.Shares of the medical device manufacturer witnessed a gain of 6% over the previous month, beating the performance of the Medical sector with its gain of 0.38% and the S&P 500's gain of 2%.Analysts and investors alike will b ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific currently has an ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 5.2% over the past month. The stock hit a new 52-week high of $84.89 in the previous session. Boston Scientific has gained 44.8% since the start of the year compared to the 11.6% move for the Zacks Medical sector and the 15.8% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't misse ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Develope ...

文章核心观点 - 波士顿科学公司(BSX)获得FDA批准,扩大INGEVITY+起搏导线的适应症范围,可用于导管引导左束支区域(LBBA)的起搏和感应 [1][3][4] - 这一批准有助于波士顿科学公司在心脏病学领域的持续发展,预计将提升市场对BSX股票的乐观情绪 [2] - LBBA起搏是传统右室起搏的替代方案,可促进更好的心室同步性,降低长期心力衰竭风险 [3] - 该适应症扩展有助于提升医生的植入体验,根据患者特点选择最合适的起搏策略 [3] 根据目录分别总结 FDA批准详情 - 临床证据包括约400名患者的INSIGHT-LBBA研究数据,证明该导线用于LBBA起搏是安全有效的 [3][4] - 这一批准紧随波士顿科学CSP产品组合的推出,包括OneLINK分线器电缆、INGEVITY+螺旋锁定工具和部位选择性起搏输送导管 [5] 行业前景 - 预计到2031年,起搏导线市场规模将从2024年的56.8亿美元增长至78亿美元,复合年增长率为4.43% [6] - 主要驱动因素包括心血管疾病患病率上升、技术进步以及微创手术偏好增加 [6] 公司最新动态 - 公司完成收购Silk Road Medical Inc,将TCAR平台带给更多医生和患者 [7] - 过去一年,BSX股价上涨55.7%,优于同行业20.3%的涨幅 [8] 公司评级及同行表现 - BSX目前被评为买入评级,同行TMDX、AXGN和KIDS也表现出色 [9][10] - TMDX 2024年每股收益预期上调2.5%至1.23美元,过去一年股价上涨156.5% [9] - AXGN 2024年每股亏损预期维持在1美分,过去一年股价上涨165.9% [10] - KIDS 2024年每股亏损预期下调至92美分,过去一年股价下跌0.8% [10]

文章核心观点 - 公司最近一个交易日的股价下跌1.19%,低于标普500指数的涨幅 [1] - 公司过去一个月的股价上涨6.14%,超过医疗行业和标普500指数的涨幅 [1] - 公司即将公布的季度财报预计每股收益将同比增长16%,收入同比增长14.34% [1] - 全年来看,公司的每股收益和收入预计将分别同比增长17.07%和14.18% [2] 公司相关 - 分析师对公司的预测数据有所调整,反映了对公司业务和盈利能力的乐观预期 [2] - 公司当前的市盈率为34.81,高于行业平均水平25.29 [3] - 公司的PEG比率为2.77,高于行业平均水平2.08 [3] 行业相关 - 公司所在的医疗器械行业目前在250多个行业中排名前26% [4] - 研究显示,排名前50%的行业相比后50%的行业表现要好2倍 [4]

Boston Scientific Co NYSE: BSX is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs. The company has a vast portfolio of devices to diagnose and treat medical conditions. The medical technology (medtech) company benefits from the aging population and the chronic diseases that come with it.Get Boston Scientific alerts:Acquiring Silk Road Medical for $1.5 BillionBoston Scientific TodayBSXBoston Scientific$83.51 +0.20 (+0.24%) 52-Week Range$48 ...

Boston Scientific (BSX) closed at $82.94 in the latest trading session, marking a -0.14% move from the prior day. This change lagged the S&P 500's 1.07% gain on the day. At the same time, the Dow added 0.31%, and the tech-heavy Nasdaq gained 2.17%.The medical device manufacturer's stock has climbed by 9.4% in the past month, exceeding the Medical sector's gain of 3.34% and the S&P 500's gain of 2.92%.The upcoming earnings release of Boston Scientific will be of great interest to investors. The company is ex ...